Simpler Grants.gov #PAR-24-304

NIH Grant for Clinical Validation of Cancer Biomarker Assays

This opportunity from the National Institutes of Health (NIH), specifically the National Cancer Institute (NCI), invites applications for research grants focused on the clinical validation of cancer biomarker assays. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Scope of Work: - Clinical validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, treatment response prediction, and cancer control/prevention - Research may include acquisition of well-annotated specimens from NCI-supported or other clinical trials and observational cohorts - Multidisciplinary collaboration is encouraged (scientific investigators, assay developers, clinicians, statisticians, clinical laboratory staff) - Products/Services Requested: - Research services for adapting and validating cancer biomarker assays - No specific commercial products, OEMs, or part numbers are named - Unique Requirements: - Early-stage technology development and the conduct of clinical trials are excluded - Focus is on preparing assays for potential integration into clinical trials as investigational tools or devices - Wide eligibility: government entities, nonprofits, businesses, educational institutions, and other organizations may apply

Description

This Notice of Funding Opportunity (NOFO) aims to accelerate the translation of NCI-supported assays to clinical use, focusing on the adaptation and clinical validation of biomarkers for cancer detection, diagnosis, prognosis, monitoring, treatment response prediction, and cancer control and prevention. Research may support acquiring well-annotated specimens from clinical trials or cohorts for assay validation. The NOFO encourages multidisciplinary collaboration among investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. It does not support early-stage technology development or clinical trials but focuses on assay adaptation and validation for potential integration into clinical trials.

View original listing